MTACW (MedTech Acquisition) Short-Term Debt: $3.33 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MTACW MedTech Acquisition Corp MTACW
22 GF Score
Price $0.22
! 2 Warning Signs
View Full Analysis

What is MedTech Acquisition Short-Term Debt?

MedTech Acquisition MTACW +21.11% 22 Short-Term Debt is $3.33 Mil as of Jun. 2023. GuruFocus rates MTACW with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

MedTech Acquisition's Short-Term Debt for the quarter that ended in Jun. 2023 was $3.33 Mil.

MedTech Acquisition's quarterly Short-Term Debt increased from Dec. 2022 ($0.98 Mil) to Mar. 2023 ($3.02 Mil) and increased from Mar. 2023 ($3.02 Mil) to Jun. 2023 ($3.33 Mil).

MedTech Acquisition's annual Short-Term Debt increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.54 Mil) and increased from Dec. 2021 ($0.54 Mil) to Dec. 2022 ($0.98 Mil).

MedTech Acquisition Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

MedTech Acquisition Short-Term Debt Related Terms

MedTech Acquisition Short-Term Debt Historical Data

* Premium members only.

The historical data trend for MedTech Acquisition's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedTech Acquisition Short-Term Debt Chart

MedTech Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Short-Term Debt
0.00 0.54 0.98

MedTech Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.94 0.98 3.02 3.33
MTACW
22GF Score
MedTech Acquisition Corp MTACW
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $3.33 Mil mean?
MedTech Acquisition (MTACW) has a Short-Term Debt of $3.33 Mil as of Jun. 2023.
Is MedTech Acquisition's Short-Term Debt too high?
MedTech Acquisition's current Short-Term Debt is $3.33 Mil. Overall, MedTech Acquisition has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does MedTech Acquisition's Short-Term Debt compare to MON and HCII?
MedTech Acquisition's Short-Term Debt of $3.33 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Diversified Financial Services company?
A good Short-Term Debt depends on the Diversified Financial Services industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. MedTech Acquisition's current Short-Term Debt is $3.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedTech Acquisition stock overvalued right now?
MedTech Acquisition (MTACW) has a current Short-Term Debt of $3.33 Mil. The current Short-Term Debt is $3.33 Mil. MedTech Acquisition's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For MedTech Acquisition (MTACW), the current Short-Term Debt is $3.33 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedTech Acquisition Business Description

Address 48 Maple Avenue, Greenwich, CT, USA, 06830
MedTech Acquisition Corp is a blank check company.
22GF Score

Get the complete analysis for MTACW

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.22
Price